Seroprevalence and factors associated with hepatitis B virus infection in blood donors in Ethiopia: a systematic review and meta-analysis

Fite, Robera Olana; Kooti, Wesam; Azeze, Gedion Asnake; Tesfaye, Bizuayehu; Hagisso, Shemsu Nuriye

doi:10.1007/s00705-020-04591-w

Cited by 11 publications

(11 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The result of a modeling study in 2016 showed the global prevalence of HBsAg-positive HB was 3.9% (95% uncertainty interval [UI], 3.4-4.6) [3]. Finally, the highest rates of HB are reported in Africa and East Asia [4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS)

et al. 2021

View full text Add to dashboard Cite

Objective Hepatitis B (HB) and C (HC) are two severe viral infectious diseases with a deleterious impact on global health. This study aimed to evaluate the prevalence of HB and HC in the Prospective Epidemiological Research Studies of the Iranian Adults (PERSIAN) Guilan Cohort Study using immunological and molecular methods. Results The blood samples were obtained from 10,520 enrolled participants. Complete biochemical and hematological tests, as well as urine analysis, were assessed. The presence of HBsAg, anti-HBs, anti-HBc, and anti-HCV antibodies for all participant and HBeAg and anti-HBe antibodies for HB-positive patients were evaluated. Moreover, HB genomic DNA and HC genomic RNA were extracted from serum samples of HB-positive patients. The real-time PCR assay was employed to quantify the gene copies of hepatitis B and C viruses. HC genotyping was also performed. The prevalence of HB and HC was 0.24% (95% CI 0.16–0.35) and 0.11% (95% CI 0.06–0.19), respectively. Rural participants were significantly more HB-positive than the urban people (P = 0.045), while males were significantly more HC-positive than the females (P = 0.013). The prevalence of HB and HC in this area were lower than those of other geographical locations of Iran, which may be due to different lifestyles or other unknown reasons.

show abstract

Section: Introductionmentioning

confidence: 99%

Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This study highlights simultaneous infection with HBV-HDV or HCV in women with chronic HBV and their infants, indicating that such a concomitant infection rapidly progresses to chronic liver diseases, liver failure, and mortality in patients. The incidence rates of HCV and HBV vary globally and depend on geographical areas and demographic characteristics (9). The prevalence of HCV-Ab among the general population of Iran was estimated to be 0.3% (34).…”

Section: Discussionmentioning

confidence: 99%

“…It is believed that the majority of patients acquired HBV infection during their perinatal or early childhood period, especially in highly endemic regions (7). Notably, even in areas with low endemic transmission rates, infections in the perinatal period or early childhood could account for more than a third of chronic infections (8)(9)(10)(11). Hepatitis C virus (HCV) is thought to be a major cause of chronic hepatic disorders, which could ultimately lead to the development of HCC and impose a significant economic burden on patients (12).…”

Section: Introductionmentioning

confidence: 99%

Determining the Prevalence of Hepatitis Delta Virus, Hepatitis C Virus, and HIV Among Mothers and Infants with Hepatitis B Virus Chronic Infection

Naderi

Hosseini

Behnampour

et al. 2022

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Infection with hepatitis B, C, and delta viruses (HBV/HCV/HDV) caused by mother-to-child transmission (MTCT) is still a serious health problem worldwide. Coinfection with HBV/HDV or HCV has been shown to accelerate the progression of chronic HBV infection, resulting in higher mortality. Objectives: The aim of this study was to evaluate the prevalence of anti-HCV, anti-HDV, and anti-HIV antibodies in mothers with chronic HBV infection and their infants. Methods: This cross-sectional study was performed on 100 mothers with chronic HBV (hepatitis B surface antigen-positive [HBsAg+]/hepatitis B core antibody-positive [HBcAb+]) and their infants between 2020 and 2021 in northeastern Iran. The presence of serological markers of HBV, anti-HCV, anti-HDV, and HIV antibodies, as well as the liver function tests, were evaluated in all mothers. The obtained data were analyzed using SPSS version 20, and the level of the statistical significance was set at a P-value < 0.05. Results: The mean age in all individuals was 37.45 ± 17.95 years. In mothers with chronic HBV and their infants, 3%, 11%, and 15% were serologically positive for anti-HCV, HCV/HDV, and anti-HDV, respectively. Also, all participants were serologically negative for anti-HIV. A statistical analysis showed a significant correlation of anti-HDV (95% CI, 0.113 - 0.332) with education, place of residence, and anti-HCV (95% CI, 0.313 - 0.416) in mothers with chronic HBV. The percentages of mothers and infants with simultaneous infection HBV were reported to be 1%, 2%, and 1% when anti-HCV, anti-HDV, and anti-HCV/HDV antibodies were measured, respectively. Conclusions: Intellectual strategies in the diagnosis of HCV, HIV, and HDV in patients with chronic HBV have challenged public and global health, and preventing viral infections in newly born infants is the most effective way to control the HBV/HCV or HDV epidemic.

show abstract

“…HBV is a hepatotropic non-cytopathic DNA virus, and unlike a self-limiting HAV infection, HBV generates a covalently closed circular DNA (cccDNA) intermediate in the nucleus of infected cells and integrates sequences that act as transcription templates for viral proteins (Fanning et al, 2019). According to the WHO, most HBV-infected persons become chronic carriers; 27 million people (10.5% of all the people estimated to be living with HB) were aware of their infection (Fite et al, 2020;WHO, 2020b). Vaccination is the most effective approach of preventing infection with the HAV and HBV.…”

Section: Discussionmentioning

confidence: 99%

The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study

Wang

Luo

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

ObjectivesTo compare the safety, immunogenicity, and immune persistence of hepatitis A (HA) vaccines between HBs-Ag-positive and -negative participants.Method9000 participants were enrolled in the phase IV study of live attenuated HA (HA-L) or inactivated HA (HA-I) vaccines. The HBs-Ag-positive subjects were detected and became an independent observation group. Adverse reactions (ARs), geometric mean concentrations (GMCs) and seroconversion rates (SRs) of the vaccines were analyzed at five time points until three years after vaccination. Results: 120 HBs-Ag-positive subjects were screened out, only 1 participant had grade 1 experienced ARs after HA-L injection. Except the time point of two years, the SRs of HBs-Ag-positive group were 100% for both vaccines. The GMCs were not statistically different between HBs-Ag-positive and -negative groups after the HA-L vaccination. The logarithmically transformed GMCs for HBs-Ag-positive and -negative groups were 3.21 mIU/mL (95% CI, 2.03-4.39 mIU/mL) and 2.95 mIU/mL (95% CI, 2.88-3.02 mIU/mL) 28 days after the HA-L vaccination, respectively.ConclusionsBoth HA-L and HA-I vaccines were safe for HBs-Ag-positive participants and may provide an excellent long-term protection against HAV in this study. The results indicated that people positive or negative for HBs-Ag can receive both HA-L and HA-I vaccines (ClinicalTrials.gov number, NCT02601040).

show abstract

Seroprevalence and factors associated with hepatitis B virus infection in blood donors in Ethiopia: a systematic review and meta-analysis

Cited by 11 publications

References 50 publications

Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS)

Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS)

Determining the Prevalence of Hepatitis Delta Virus, Hepatitis C Virus, and HIV Among Mothers and Infants with Hepatitis B Virus Chronic Infection

The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study

Contact Info

Product

Resources

About